| 1.38 -0.13 (-8.61%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.65 | 1-year : | 3.95 |
| Resists | First : | 2.27 | Second : | 3.39 |
| Pivot price | 1.45  |
|||
| Supports | First : | 0.46 | Second : | 0.38 |
| MAs | MA(5) : | 1.56 |
MA(20) : | 1.22 |
| MA(100) : | 2.2 |
MA(250) : | 4.44 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 34 |
D(3) : | 37.5 |
| RSI | RSI(14): 53.3 |
|||
| 52-week | High : | 9.5 | Low : | 0.46 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VRPX ] has closed above bottom band by 41.1%. Bollinger Bands are 40.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.55 - 1.56 | 1.56 - 1.57 |
| Low: | 1.33 - 1.34 | 1.34 - 1.35 |
| Close: | 1.36 - 1.38 | 1.38 - 1.4 |
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Fri, 26 Jul 2024
Virpax Pharmaceuticals pays off $2.5 million secured note early - Investing.com
Fri, 26 Jul 2024
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update - Defense World
Wed, 24 Jul 2024
Virpax Regains Compliance with Nasdaq Minimum Bid Price - Business Wire
Wed, 24 Jul 2024
Virpax Regains Compliance with Nasdaq Minimum Bid Price - StockTitan
Sat, 20 Jul 2024
Virpax Pharmaceuticals (NASDAQ:VRPX) Upgraded by Maxim Group to Buy - American Banking and Market News
Wed, 10 Jul 2024
Pain Management-Focused Penny Stock Virpax Pharmaceuticals Surges Over 100% On Wednesday-Here's Why? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 6.2 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 37 (K) |
| Shares Short P.Month | 57 (K) |
| EPS | -14.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.04 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -77.2 % |
| Return on Equity (ttm) | -241.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | -1.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|